/IVA
IVA Stock - Inventiva S.A.
Healthcare|BiotechnologyNASDAQ
$4.21+0.24%
+$0.01 (+0.24%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.47
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+208.8%upside
Target: $13.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.17 – $4.25
TARGET (TP)$13.00
STOP LOSS$3.87
RISK/REWARD1:25.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.78
52W High$7.98
52W Low$2.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.20M | $17.48M | $12.18M | $4.19M | $372,000 |
| Gross Profit | $9.20M | $17.50M | $17.06M | $4.19M | $4.42M |
| Gross Margin | 100.0% | 100.1% | 140.1% | 100.0% | 1187.4% |
| Operating Income | $-97,558,000 | $-102,709,000 | $-57,110,000 | $-52,114,000 | $-29,718,000 |
| Net Income | $-184,212,000 | $-110,426,000 | $-54,274,000 | $-49,636,000 | $-33,619,000 |
| Net Margin | -2002.7% | -631.8% | -445.6% | -1183.5% | -9037.4% |
| EPS | $-3.54 | $-2.43 | $-1.31 | $-1.27 | $-0.99 |
Company Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
78%
Hold / Neutral
1
11%
Sell / Underperform
1
11%
Analyst Consensus🟢 Bullish
7 Bullish2 Neutral/Bearish
Price Targets
$15
Average Target
↑ 262.2% Upside
Now
$3
Low
$15
Average
$27
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 6th 2025 | Wolfe Research | Initiation | Outperform | $13 |
| September 3rd 2025 | H.C. Wainwright | Resumed | Buy | $20 |
| August 27th 2025 | Piper Sandler | Initiation | Overweight | $26 |
| February 21st 2025 | TD Cowen | Initiation | Buy | $10 |
| November 12th 2024 | UBS | Initiation | Neutral | $3 |
| October 27th 2023 | Canaccord Genuity | Initiation | Buy | $12 |
| May 31st 2023 | ROTH MKM | Initiation | Buy | $11 |
| May 19th 2023 | Societe Generale | Upgrade | Buy | - |
| March 17th 2023 | Stifel | Initiation | Buy | $27 |
| November 15th 2022 | Societe Generale | Downgrade | Sell | - |
Earnings History & Surprises
IVABeat Rate
45%
Last 11 quarters
Avg Surprise
-89.9%
EPS vs Estimate
Beats / Misses
5/6
Last 12 quarters
Latest EPS
$-1.89
Q3 2025
EPS Surprise History
Q1 22
+15.3%
$-0.76vs$-0.90
Q3 22
+16.6%
$-0.75vs$-0.90
Q1 23
-11.9%
$-0.64vs$-0.57
Q3 23
-13.1%
$-1.43vs$-1.27
Q1 24
-211.7%
$-1.25vs$-0.40
Q3 24
-81.1%
$-1.01vs$-0.56
Q2 25
-472.9%
$-2.69vs$-0.47
Q3 25
-361.7%
$-1.89vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | $-0.41 | $-1.89 | -361.7% | ✗ MISS |
Q2 2025 | May 23, 2025 | $-0.47 | $-2.69 | -472.9% | ✗ MISS |
Q3 2024 | Sep 25, 2024 | $-0.56 | $-1.01 | -81.1% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.40 | $-1.25 | -211.7% | ✗ MISS |
Q3 2023 | Sep 28, 2023 | $-1.27 | $-1.43 | -13.1% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.57 | $-0.64 | -11.9% | ✗ MISS |
Q3 2022 | Sep 19, 2022 | $-0.90 | $-0.75 | +16.6% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.90 | $-0.76 | +15.3% | ✓ BEAT |
Q3 2021 | Sep 20, 2021 | $-0.91 | $-0.46 | +49.0% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | $-0.82 | $-0.57 | +30.0% | ✓ BEAT |
Q3 2020 | Sep 16, 2020 | $-0.69 | $-0.32 | +53.2% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | — | $-0.41 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.05 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.91 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-1.00 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.67 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.76 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.31 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.45 | — | — |
Latest News
Guggenheim Maintains Buy on Inventiva, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 18, 2025, 02:16 PM
Inventiva Announced That The Underwriters Of The Previously Announced Public Offering Have Exercised In Full Their Option To Purchase 5.84M Additional American Depositary Shares
📈 PositiveBenzinga•Nov 17, 2025, 10:34 AM
Inventiva Prices U.S. Offering Of 38.96M ADSs At $3.85 Each; Settlement Expected November 17
➖ NeutralBenzinga•Nov 13, 2025, 02:24 PM
Inventiva Halts Trading Of Ordinary Shares On Euronext Paris Pending Allocation Confirmation And Pricing Of US Offering Of New ADSs
➖ NeutralBenzinga•Nov 13, 2025, 08:25 AM•Also:
Inventiva Plans To Launch $125M American Depositary Shares Offering
➖ NeutralBenzinga•Nov 12, 2025, 09:37 PM
Wolfe Research Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $13
📈 PositiveBenzinga•Nov 6, 2025, 01:24 PM
Deputy Director Of The White House Domestic Policy Council Says New Fertility Benefit Option For Employers To Offer To Employees
📈 PositiveBenzinga•Oct 16, 2025, 08:13 PM•Also: , ,
HC Wainwright & Co. Maintains Buy on Inventiva, Raises Price Target to $24
📈 PositiveBenzinga•Oct 9, 2025, 02:36 PM
Inventiva Appoints Andrew Obenshain As CEO Succeeding Co-Founder Frédéric Cren To Lead Phase 3 MASH Therapy Commercialization
📈 PositiveBenzinga•Oct 1, 2025, 06:42 AM
Canaccord Genuity Maintains Buy on Inventiva, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 01:44 PM•Also:
Inventiva H1 EPS $(1.84) Misses $(0.41) Estimate, Sales $5.050M Miss $5.310M Estimate
📉 NegativeBenzinga•Sep 29, 2025, 07:04 AM
HC Wainwright & Co. Assumes Inventiva at Buy, Announces Price Target of $20
📈 PositiveBenzinga•Sep 3, 2025, 11:08 AM
Guggenheim Maintains Buy on Inventiva, Raises Price Target to $13
📈 PositiveBenzinga•Sep 2, 2025, 11:44 AM
Inventiva surges as Piper Sandler issues bullish view citing lead asset
📈 PositiveSeeking Alpha•Aug 27, 2025, 03:52 PM
Inventiva shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $26 price target.
📈 PositiveBenzinga•Aug 27, 2025, 01:38 PM
Piper Sandler Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $26
📈 PositiveBenzinga•Aug 27, 2025, 01:17 PM
Frequently Asked Questions about IVA
What is IVA's current stock price?
Inventiva S.A. (IVA) is currently trading at $4.21 per share. The stock has moved +0.24% today.
What is the analyst price target for IVA?
The average analyst price target for IVA is $13.00, based on 1 analyst.
What sector is Inventiva S.A. in?
Inventiva S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IVA's market cap?
Inventiva S.A. has a market capitalization of $0.22 billion, making it a small-cap company.
Does IVA pay dividends?
No, Inventiva S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
RNAC
Cartesian Therapeutics, Inc.
$7.22
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
Explore stocks similar to IVA for comparison